Psychiatric Drug Development in Japan-Reference-Cited by-同舟云学术

Psychiatric Drug Development in Japan

Published:1996-07-19 Issue:5273 Volume:273 Page:318-319
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Berger Douglas¹,Fukunishi Isao²

Affiliation:

1. D. Berger is at the Tokyo Institute of Psychiatry, 2-1-8, Kamikitazawa, Setagayaku, Tokyo 156, Japan, and at the Albert Einstein College of Medicine, Bronx, NY 10461, USA.

2. I. Fukunishi is at the Tokyo Institute of Psychiatry, 2-1-8, Kamikitazawa, Setagayaku, Tokyo 156, Japan.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference11 articles.

1. Okada F., Ann. Pharmacother. 29, 432 (1995).

2. Okada F., Hum. Psychopharmacol. 8, 371 (1993).

3. Pickar D., Hsiao J. K., J. Am. Med. Assoc. 274, 981 (1995).

4. Alvir J. M. J., et al., N. Engl. J. Med. 329, 162 (1993).

5. Mizushima Y., Nihon Enshou Gakkai Zasshi 15 2 93 1995; ibid. (no. 3), p. 193.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing;Psychiatry Investigation;2023-03-25

2. Assessing Psychiatric Adverse Effects during Clinical Drug Development;Pharmaceutical Medicine;2012-12

3. Delays in psychiatric drug development in Japan;Journal of Clinical Pharmacy and Therapeutics;2011-10-23

4. Mental health care of Western expatriates in Tokyo;Travel Medicine and Infectious Disease;2008-09

5. Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry;Strategic Management Journal;2004-07-20